Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis.
Szamosi T, Banai J, Lakatos L, Czegledi Z, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp M, Papp J, Lakatos PL. Szamosi T, et al. Eur J Gastroenterol Hepatol. 2010 Jul;22(7):872-9. doi: 10.1097/MEG.0b013e32833036d9. Eur J Gastroenterol Hepatol. 2010. PMID: 19648821
Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease.
Lakatos PL, Czegledi Z, Szamosi T, Banai J, David G, Zsigmond F, Pandur T, Erdelyi Z, Gemela O, Papp J, Lakatos L. Lakatos PL, et al. Among authors: szamosi t. World J Gastroenterol. 2009 Jul 28;15(28):3504-10. doi: 10.3748/wjg.15.3504. World J Gastroenterol. 2009. PMID: 19630105 Free PMC article.
Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study.
Miheller P, Lakatos PL, Horváth G, Molnár T, Szamosi T, Czeglédi Z, Salamon A, Czimmer J, Rumi G, Palatka K, Papp M, Jakab Z, Szabó A, Gelley A, Lakatos L, Barta Z, Balázs C, Rácz I, Zeher M, Döbrönte Z, Altorjay I, Hunyady B, Simon L, Papp J, Banai J, Nagy F, Lonovics J, Ujszászy L, Muzes G, Herszényi L, Tulassay Z. Miheller P, et al. Among authors: szamosi t. BMC Gastroenterol. 2009 Sep 10;9:66. doi: 10.1186/1471-230X-9-66. BMC Gastroenterol. 2009. PMID: 19740450 Free PMC article.
ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients.
Lakatos PL, Szamosi T, Szilvasi A, Molnar E, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Tulassay Z, Miheller P, Papp J, Tordai A, Andrikovics H; Hungarian IBD Study Group. Lakatos PL, et al. Among authors: szamosi t. Dig Liver Dis. 2008 Nov;40(11):867-73. doi: 10.1016/j.dld.2008.03.022. Epub 2008 May 22. Dig Liver Dis. 2008. PMID: 18499543
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease.
Kiss LS, Szamosi T, Molnar T, Miheller P, Lakatos L, Vincze A, Palatka K, Barta Z, Gasztonyi B, Salamon A, Horvath G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovasz BD, Vegh Z, Golovics PA, Szathmari M, Papp M, Lakatos PL; Hungarian IBD Study Group. Kiss LS, et al. Among authors: szamosi t. Aliment Pharmacol Ther. 2011 Oct;34(8):911-22. doi: 10.1111/j.1365-2036.2011.04827.x. Epub 2011 Aug 24. Aliment Pharmacol Ther. 2011. PMID: 21883326
The 3'UTR NFKBIA variant is associated with extensive colitis in Hungarian IBD patients.
Szamosi T, Lakatos PL; Hungarian IBD Study Group; Szilvasi A, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Szabo O, Satori A, Tulassay Z, Miheller P, Horvath HC, Papp J, Tordai A, Andrikovics H. Szamosi T, et al. Dig Dis Sci. 2009 Feb;54(2):351-9. doi: 10.1007/s10620-008-0351-6. Epub 2008 Aug 21. Dig Dis Sci. 2009. PMID: 18716880
Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease.
Lakatos PL, Czegledi Z, David G, Kispal Z, Kiss LS, Palatka K, Kristof T, Nagy F, Salamon A, Demeter P, Miheller P, Szamosi T, Banai J, Papp M, Bene L, Kovacs A, Racz I, Lakatos L. Lakatos PL, et al. Among authors: szamosi t. J Crohns Colitis. 2010 Sep;4(3):283-90. doi: 10.1016/j.crohns.2009.11.011. J Crohns Colitis. 2010. PMID: 21122517
[Predictors of efficacy, mucosal healing and dose intensification during the first year of adalimumab therapy in patients with luminal and fistulizing Crohn's disease. National data from Hungary].
Kiss LS, Szamosi T, Molnár T, Miheller P, Lakatos L, Vincze A, Palatka K, Bartha Z, Gasztonyi B, Salamon A, Horváth G, Tóth GT, Farkas K, Banai J, Tulassay Z, Nagy F, Szenes M, Veres G, Lovász BD, Végh Z, Golovics PA, Szathmári M, Papp M, Lakatos PL. Kiss LS, et al. Among authors: szamosi t. Orv Hetil. 2011 Sep 4;152(36):1433-42. doi: 10.1556/OH.2011.29200. Orv Hetil. 2011. PMID: 21865144 Hungarian.
Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease?
Horváth G, Farkas K, Hollósi R, Nagy F, Szepes Z, Papp M, Palatka K, Miheller P, Lakatos L, Szamosi T, Nyári T, Wittmann T, Molnár T. Horváth G, et al. Among authors: szamosi t. Scand J Gastroenterol. 2012 Nov;47(11):1298-303. doi: 10.3109/00365521.2012.703233. Epub 2012 Aug 31. Scand J Gastroenterol. 2012. PMID: 22935014
60 results